Yihan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yihan Wang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Kai Huang
Department of Pharmacology, College of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang, 050200 Hebei Province, China
1 shared publicationLinqi Yang
Department of Pharmacology, College of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang, 050200 Hebei Province, China
1 shared publication- Meng Li
Department of Pharmacology, College of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang, 050200 Hebei Province, China
1 shared publication Meng Wu
Department of Gastroenterology, Qinhuangdao Beidaihe Hospital, Qinhuangdao, 066199 Hebei Province, China
1 shared publication- Tao Sun
Department of Pharmacology, College of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang, 050200 Hebei Province, China
1 shared publication - Wenqi Zhang
Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
1 shared publication
Latest Publications
- RetractedOpen Access
- 8 August 2022
- Published by Hindawi Limited in Disease Markers
- Vol. 2022, 1-11
DDTC Suppresses Ovarian Cancer Development via the PI3K/AKT/mTOR Signaling Pathway
In prior research, 6,12-diphenyl-3,9-diazatetraasterane-1, 5, 7, 11-tetracarboxylate (DDTC) has been shown to be an effective inhibitor of the growth of the SKOV3 and A2780 ovarian cancer (OC) cell lines. Flow cytometry analyses indicated that DDTC was able to suppress P-CNA expression at the protein level within OC cells, while RNA-seq indicated that DDTC treatment was associated with marked changes in gene expression profiles within A2780 cells. Molecular docking analyses suggested that DDTC has the potential to readily dock with key signaling proteins including PI3K, AKT, and mTOR. In line with these findings, DDTC treatment inhibited the growth of xenograft tumors in a mouse model system. Such treatment was also associated with reduced p-PI3K/PI3K, p-AKT/AKT, p-mTOR/mTOR, and CyclinD1 (CCND1) expressions and with the increased expression of PTEN in vitro and in vivo. Together, these results suggest that DDTC is capable of readily inhibiting OC development at least in part via targeting and modulating signaling via the PI3K/AKT/mTOR axis.
- 8 August 2022
- Published by Hindawi Limited in Disease Markers
- Vol. 2022, 1-11
RetractedOpen AccessDDTC Suppresses Ovarian Cancer Development via the PI3K/AKT/mTOR Signaling Pathway
In prior research, 6,12-diphenyl-3,9-diazatetraasterane-1, 5, 7, 11-tetracarboxylate (DDTC) has been shown to be an effective inhibitor of the growth of the SKOV3 and A2780 ovarian cancer (OC) cell lines. Flow cytometry analyses indicated that DDTC was able to suppress P-CNA expression at the protein level within OC cells, while RNA-seq indicated that DDTC treatment was associated with marked changes in gene expression profiles within A2780 cells. Molecular docking analyses suggested that DDTC has the potential to readily dock with key signaling proteins including PI3K, AKT, and mTOR. In line with these findings, DDTC treatment inhibited the growth of xenograft tumors in a mouse model system. Such treatment was also associated with reduced p-PI3K/PI3K, p-AKT/AKT, p-mTOR/mTOR, and CyclinD1 (CCND1) expressions and with the increased expression of PTEN in vitro and in vivo. Together, these results suggest that DDTC is capable of readily inhibiting OC development at least in part via targeting and modulating signaling via the PI3K/AKT/mTOR axis.